Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.8.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Operating Costs and Expenses:    
General and administrative $ 1,620 $ 2,090
Research and development 3,370 6,059
Total Operating Costs and Expenses 4,990 8,149
Loss from Operations (4,990) (8,149)
Other Income:    
Change in fair value of warrant liability 2,655 5,090
Interest income 9 1
Total Other Income 2,664 5,091
Net Loss (2,326) (3,058)
Net Loss Attributable to Non-controlling Interest (10) (212)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (2,316) (2,846)
Series A Preferred Stock Dividends (59) 0
Net Loss Attributable to Common Stock Holders $ (2,375) $ (2,846)
Net Loss Per Share - Basic and Dilutive $ (0.02) $ (0.02)
Weighted average number of shares outstanding during the period - Basic and Dilutive 128,566,883 117,447,260